IDEAYA Biosciences, Inc. (BST:30J)
Germany
· Delayed Price · Currency is EUR | Market Cap | 2.21B |
| Revenue (ttm) | 186.28M |
| Net Income (ttm) | -96.84M |
| Shares Out | n/a |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 86 |
| Open | 25.89 |
| Previous Close | 26.08 |
| Day's Range | 25.05 - 26.50 |
| 52-Week Range | 18.30 - 32.60 |
| Beta | n/a |
| RSI | 38.59 |
| Earnings Date | May 6, 2026 |
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial numbers in USDNews
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-b...
IDEAYA Biosciences Transcript: Study result
Darovasertib plus crizotinib significantly improved progression-free survival and response rates in HLA-A2 negative metastatic uveal melanoma, with a favorable safety profile and early signs of overall survival benefit. The combination is poised to become a new standard, with ongoing studies in broader patient populations and earlier disease settings.
Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results
The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30, ...
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pr...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,0...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs ...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for thr...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in MTAP-deleted cell lines IDE892 is being evaluate...
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
BEIJING--(BUSINESS WIRE)-- #Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of ...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034 Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161 B7H3/PTK7 co-expressed in 30-40% ...
IDEAYA Biosciences Transcript: Status update
Darovasertib's phase III trial in metastatic uveal melanoma has completed enrollment, with top-line PFS data expected by end of March and NDA filing targeted for later this year. The pipeline includes promising ADC, MTAP, and KAT6/7 programs, with rapid neoadjuvant and combination studies underway.
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo...
IDEAYA Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
Upcoming top-line data for darovasertib/crizotinib in metastatic uveal melanoma is expected by end of March, with strong prior efficacy signals. Multiple pipeline assets are advancing, including ADCs and MTAP-targeted therapies, with key readouts and regulatory filings planned over the next two years.
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
130 required PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM); topline results expected b...
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Feb. 2, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
IDEAYA Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Revised summary: The presentation highlighted a strong oncology pipeline with nine clinical-stage assets, including darovasertib, nearing top-line results for metastatic uveal melanoma and FDA Breakthrough Therapy Designation. Strategies focus on ADC durability, MTAP deletion, and next-gen inhibitors, with pivotal studies and data readouts expected soon.
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of k...
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential a...
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026 Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumo...
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, ha...
IDEAYA Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference
Key clinical milestones are approaching for Darovasertib in uveal melanoma, with pivotal PFS data expected soon and multiple registrational trials underway. Promising results in DLL3 ADC and MTAP pathway programs highlight a robust pipeline, with several data updates and new combination strategies planned for next year.